MX2014006514A - Benzimidazoles y benzopirazoles sustituidos como antagonistas de ccr(4). - Google Patents

Benzimidazoles y benzopirazoles sustituidos como antagonistas de ccr(4).

Info

Publication number
MX2014006514A
MX2014006514A MX2014006514A MX2014006514A MX2014006514A MX 2014006514 A MX2014006514 A MX 2014006514A MX 2014006514 A MX2014006514 A MX 2014006514A MX 2014006514 A MX2014006514 A MX 2014006514A MX 2014006514 A MX2014006514 A MX 2014006514A
Authority
MX
Mexico
Prior art keywords
ccr
benzopyrazoles
antagonists
substituted benzimidazoles
diseases
Prior art date
Application number
MX2014006514A
Other languages
English (en)
Other versions
MX354955B (es
Inventor
Manmohan Reddy Leleti
Yandong Li
Venkat Reddy Mali
Jay Powers
Ju Yang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2014006514A publication Critical patent/MX2014006514A/es
Publication of MX354955B publication Critical patent/MX354955B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan compuestos de benzimidazol, benzopirazol y benzotriazol que se unen a CCR(4) y son útiles para el tratamiento de enfermedades tales como enfermedades alérgicas, enfermedades autoinmunes, rechazo de injerto y cáncer.
MX2014006514A 2011-12-01 2012-11-30 Benzimidazoles y benzopirazoles sustituidos como antagonistas de ccr(4). MX354955B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161565973P 2011-12-01 2011-12-01
PCT/US2012/067299 WO2013082429A1 (en) 2011-12-01 2012-11-30 Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists

Publications (2)

Publication Number Publication Date
MX2014006514A true MX2014006514A (es) 2014-07-10
MX354955B MX354955B (es) 2018-03-27

Family

ID=47324474

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006514A MX354955B (es) 2011-12-01 2012-11-30 Benzimidazoles y benzopirazoles sustituidos como antagonistas de ccr(4).

Country Status (13)

Country Link
US (4) US8685959B2 (es)
EP (1) EP2785710B1 (es)
JP (1) JP6141863B2 (es)
KR (1) KR102031846B1 (es)
CN (1) CN103974950B (es)
AU (1) AU2012345779B2 (es)
BR (1) BR112014013150A2 (es)
CA (1) CA2856831C (es)
DK (1) DK2785710T3 (es)
ES (1) ES2648340T3 (es)
MX (1) MX354955B (es)
PT (1) PT2785710T (es)
WO (1) WO2013082429A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9361365B2 (en) 2008-05-01 2016-06-07 Primal Fusion Inc. Methods and apparatus for searching of content using semantic synthesis
DK2785710T3 (en) 2011-12-01 2017-12-04 Chemocentryx Inc SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR (4) - ANTAGONISTS
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物
JP6461118B2 (ja) 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規の置換された二環式化合物
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規キナゾリノン
GB201321740D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
CN104622874B (zh) * 2015-02-15 2017-12-26 中国科学院生物物理研究所 Ccr4拮抗剂在抑制癌生长及转移中的应用
AU2017302635B2 (en) * 2016-07-29 2021-09-16 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
US10246462B2 (en) 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
EP3548034A4 (en) * 2016-12-05 2020-07-08 Microbiotix, Inc. BROAD SPECTRUM INHIBITORS OF FILOVIRUS
WO2018187509A1 (en) * 2017-04-04 2018-10-11 Flx Bio, Inc. Heterocyclic compounds as chemokine receptor modulators
US10800760B2 (en) 2017-05-31 2020-10-13 Nantbio, Inc. Trk inhibition
EP3706750A1 (en) * 2017-11-06 2020-09-16 RAPT Therapeutics, Inc. Chemokine receptor modulators for treatment of epstein barr virus positive cancer
DK3743418T3 (da) 2018-01-26 2024-09-09 Rapt Therapeutics Inc Chemokinreceptormodulatorer og anvendelser deraf
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
ES3064674T3 (en) 2019-10-16 2026-04-28 Chemocentryx Inc Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
JP7736678B2 (ja) 2019-10-16 2025-09-09 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド
CN118475581A (zh) * 2022-01-25 2024-08-09 瑞石生物医药有限公司 一种ccr4小分子拮抗剂及其用途
KR20230149729A (ko) * 2022-04-19 2023-10-27 케모센트릭스, 인크. Ccr4 길항제
CN119638669A (zh) * 2023-09-15 2025-03-18 上海医药集团股份有限公司 一种趋化因子受体拮抗剂、药物组合物和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
AU3899097A (en) * 1996-08-05 1998-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted aromatic compounds
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AU2005298986A1 (en) * 2004-10-27 2006-05-04 F. Hoffmann-La Roche Ag New indole or benzimidazole derivatives
MX2007010068A (es) * 2005-02-16 2007-10-10 Schering Corp Piperazino-piperidinas con actividad antagonista de cxcr3.
WO2007111227A1 (ja) * 2006-03-24 2007-10-04 Astellas Pharma Inc. アシルアミノピペリジン化合物
JP2010208945A (ja) * 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
EP2419419B1 (en) * 2009-04-17 2014-12-03 Janssen Pharmaceutica NV 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
DK2785710T3 (en) 2011-12-01 2017-12-04 Chemocentryx Inc SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR (4) - ANTAGONISTS

Also Published As

Publication number Publication date
US20180127395A1 (en) 2018-05-10
CA2856831C (en) 2020-02-18
US9790204B2 (en) 2017-10-17
CN103974950B (zh) 2016-12-21
KR20140097552A (ko) 2014-08-06
DK2785710T3 (en) 2017-12-04
WO2013082429A1 (en) 2013-06-06
US9150550B2 (en) 2015-10-06
MX354955B (es) 2018-03-27
US20160185756A1 (en) 2016-06-30
JP2015500240A (ja) 2015-01-05
ES2648340T3 (es) 2018-01-02
KR102031846B1 (ko) 2019-10-14
BR112014013150A2 (pt) 2017-06-13
US20130165423A1 (en) 2013-06-27
CA2856831A1 (en) 2013-06-06
JP6141863B2 (ja) 2017-06-07
EP2785710A1 (en) 2014-10-08
AU2012345779A1 (en) 2014-06-12
US8685959B2 (en) 2014-04-01
EP2785710B1 (en) 2017-09-20
PT2785710T (pt) 2017-12-18
AU2012345779B2 (en) 2017-04-06
HK1202866A1 (en) 2015-10-09
CN103974950A (zh) 2014-08-06
US20140121195A1 (en) 2014-05-01
US10647696B2 (en) 2020-05-12

Similar Documents

Publication Publication Date Title
MX2014006514A (es) Benzimidazoles y benzopirazoles sustituidos como antagonistas de ccr(4).
MX356163B (es) Anilinas sustituidas como antagonistas de ccr(4).
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
PH12012501783A1 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
EA201690461A1 (ru) Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
WO2013169574A3 (en) Aliphatic spirolactam cgrp receptor antagonists
IN2015MN00478A (es)
EA201171367A1 (ru) Винилиндазолильные соединения
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
MX2012001419A (es) Compuestos biciclicos novedosos de urea.
MX353299B (es) Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
JO3092B1 (ar) مركب لتحفيز مسيطر عليه للمبيض
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
EA201590962A1 (ru) Новые соединения
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX360774B (es) Antagonistas de progesterona.
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
MX342947B (es) Tratamiento de diabetes tipo 2.
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3

Legal Events

Date Code Title Description
FG Grant or registration